Abstract:It has been reported that positive remodeling, regression of neointimal hyperplasia, and late malapposition are associated with brachytherapy, one of the approaches to prevent first-time and recurrent in-stent restenosis.1,2 Recently, some drug-eluting stents have been demonstrated to dramatically reduce restenosis rates.3,4 Despite these promising results, these drug-eluting stents may have the same potential risks as brachytherapy, with some similarities between the 2 technologies in anti- proliferative effects on vascular smooth muscle cells and endothelial cells. We reported a case of late stent malapposition and marked positive vessel remodeling after sirolimus-eluting coronary stent implantation. CASE REPORT The patient was a 32-year-old male admitted in the hospital on August 23, 2004 because of chest oppression after subacute anterior myocardial infarction. He had no cardiac risk factors except smoking. Coronary angiogram showed a total occlusion of the proximal left anterior descending artery (LAD), and a successful angioplasty was performed using a 3.0 mm×28 mm sirolimus-eluting Cypher SelectTM stent (Cordis, USA) with the pressure of 1419 kPa after predilatation (Fig. A). Intravascular ultrasound (IVUS) imaging showed complete apposition of the stent struts against the vessel wall over the entire length of the stent (Fig. B).Fig.: Angiographic (A) and IVUS (B) pictures of left anterior descending artery immediately after Cypher implantation. Angiographic (C) and IVUS (D) pictures at 9 months follow up. The white arrows indicate a “zig-zag” phenomenon (C) and lacunar spaces beyond the stent struts, in which blood flow is evident (D). Compared with the baseline IVUS, a significant increase in vessel CSA and plaque CSA is found at follow up, indicative of marked positive vessel remodeling. IVUS: Intravascular ultrasound, CSA: cross-sectional area.Nine months later, repeated coronary angiography by scheduled follow up was performed and a “zig-zag” phenomenon in the stented segment was found (Fig. C). Subsequent IVUS imaging found that there were several gaps between the struts of the stent and the vessel wall, indicating the late acquired stent malapposition. Quantitative measurement showed a significant enlargement in external elastic membrane (EEM) cross-sectional area (CSA, 14.1 mm2 at baseline, 29.9 mm2 at follow up) and in plaque and media CSA (from 7.6-20.5 mm2, Fig. D), indicating marked positive vessel remodeling. The maximum depth between stent struts and the vessel wall was 1.0 mm. There was no change in stent CSA, and the effective lumen increased because of the late malapposition. The increase in EEM area (25.8 mm2) was larger than that in plaque and media CSA (12.9 mm2). In stent segment, the EEM area of the stent segment was significantly larger than that of the average reference segment, with a remodeling index of 1.9, and the maximum vessel diameter was extraordinarily large with stent malapposition, reaching 6.5 mm. Because of the lack of information regarding malapposition as the cause of subacute occlusion in drug-eluting stent, the patient did not undergo any further interventional therapy and was suggested to take clopidogrel for long time and will be closely followed up with repeated angiography and IVUS to assess the potential progression of the malapposition. DISCUSSION Late stent malapposition, a separation of the stent struts from the intimal surface of the arterial wall that is not present immediately after implantation, has been previously documented after brachytherapy and bare-metal stent implantation.1,2,5 A subgroup analysis of the RAVEL trial reveals a late stent malapposition after SES implantation with an significantly higher incidence than bare-metal stent.3 But the mechanistic interpretation of these data are hampered by the fact that no IVUS analysis had been performed during the baseline procedure. Thus, it is unclear whether the stents are already incompletely apposed against the vessel wall during the index procedure or this is a late acquired effect. In the present case report, serial IVUS was performed and revealed late stent malapposition at follow up, with complete apposition of the stent struts against the vessel wall over the entire length of the stent at baseline. No significant change in stent, plaque behind stent, and vessel volume is described after SES implantation by Degertekin et al.6 However, significant vascular positive remodeling is demonstrated by ectatic areas of vessel and plaque behind stent compared with the index parameters in the present case with late stent malapposition. The findings suggest that late stent malapposition after SES implantation may be associated with an increase in EEM (positive remodeling) out of proportion to the increase in peri-stent tissue hyperplasia. In the situation of malapposition, there are some gaps between the stent struts and the vessel wall. These gaps could be filled by contrast media during angiography and appeared as the “zig-zag”phenomenon just in the stented segment. Whether the late stent malapposition will be the potential mechanism of late in-stent thrombosis remains further investigation and long-term follow up of the patient receiving drug-eluting stent.

Coexistent In-Stent Restenosis, Late Incomplete Stent Apposition and Mural Thrombus in a Zotarolimus-Eluting Stent.

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENTS VERSUS THE FIRST GENERATION SIROLIMUS-ELUTING STENTS AND PACLITAXEL-ELUTING STENTS: A META-ANALYSIS OF RANDOMISED TRIALS

Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Drug-Eluting Stent and Late Stent Thrombosis

Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China

Real World Clinical Performance of the Zotarolimus Eluting Coronary Stent System in Chinese Patients: a Prospective, Multicenter Registry Study.

A More Than 2-Year Follow-Up of Incomplete Apposition after Drug-Eluting Stent Implantation

Efficacy and Safety of Drug-Eluting Stent Implantation for the Treatment of In-Stent Restenosis Occurring Within Bare-Metal Stent and Drug-Eluting Stent

In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Very Late Stent Thrombosis in Late Stent Malapposition After Sirolimus-Eluting Stent Implantation

Very Late Stent Thrombosis in Late Stent Malapposition after Sirolimus-Eluting Stent Implantation.

Current status and prospect of drug-eluting stents

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

Drug-Eluting Stents: Technical and Clinical Progress

Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

An Intravascular Ultrasound Study of Cypher, Taxus, and Endeavor Stents on Relation Between Neointimal Proliferation and Residual Plaque Burden

Long-term Outcomes after Resolute Zotarolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Acute Myocardial Infarction: Insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.

Late Stent Malapposition and Marked Positive Vessel Remodeling after Sirolimus-Eluting Coronary Stent Implantation